A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) is a phase 3 interventional study registered as NCT07066098, led by Innovent Biologics (Suzhou), and recruiting on the registry. Official title: A Multicenter, Randomised, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants With Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received>=2 Prior Lines of Therapy. Planned enrolment is 201 participants (estimated). The study started in 2025-08-04 and primary completion is expected in 2027-06-30. No results have been posted on ClinicalTrials.gov.